J&J Surges to Fresh Highs on Defensive Rotation

Johnson & Johnson's stock price surged 3% to $270.19 on Tuesday morning as investors rotated out of high-growth tech stocks and into defensive companies.

The Nasdaq struggled with broad selling pressure, but J&J pushed toward fresh 52-week highs as investors rewarded stability in the healthcare heavyweight.

Johnson & Johnson's consistent growth has impressed investors, with second-quarter sales climbing 6.6% to $25.31 billion and adjusted earnings reaching $2.90 per share.

The company is now approaching a milestone few healthcare giants reach: surpassing $100 billion in annual sales, with management targeting approximately $101.1 billion in revenue for 2026 at the midpoint.